Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorHospital Universitario Dr. Jose E. Gonzalez
About this trial
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Eligibility criteria
Qualifiers
Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
ECOG 0-2
Women of reproductive age who agree on getting a contraceptive method
Subjects who fulfill Lugano´s criteria for disease activity
Disqualifiers
Active bacterial, viral or fungal infection
Subjects who have already received an autologous o allogeneic stem cell transplantation
Subjects with other active neoplasias
Subjects with end-stage failure
Trial design
Treatments tested in this trial
- Epcoritamab
- Gemcitabine (1000 mg/m2)
- Oxaliplatin
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov